# CJC-1295 Dosing Context and Half-Life in Published Studies > CJC-1295 dosing context: the subcutaneous doses and 5.8-8.1 day half-life from the published research. No human-use dose is established for this unapproved peptide. What was administered, to whom, by which route — and where the human data stop. ## What the studies administered This page describes the doses and routes used in published CJC-1295 research. It is not a protocol and not a recommendation: CJC-1295 is not approved for human use, and no validated human dose exists. Human PK studies used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram [1][3]. The GHRH-knockout mouse growth study used 2 micrograms per dose at 24-, 48-, or 72-hour intervals, with the once-daily schedule restoring growth most effectively [7]. Community and clinic "protocols" for no-DAC Modified GRF 1-29 and for CJC-1295/ipamorelin commonly cite fixed 100-300 microgram doses — but those figures are not derived from controlled human trials and have no published efficacy or safety validation behind them. They are reported here only to be distinguished from the actual research doses, not endorsed. ## How Long Does CJC-1295 Stay Active? Days for the DAC form; minutes-to-hours for no-DAC. CJC-1295 DAC had an estimated half-life of 5.8 to 8.1 days in healthy adults, and IGF-1 elevation persisted up to 28 days after multiple doses [1]. The no-DAC form, Modified GRF (1-29), is short-acting — it reflects native GHRH(1-29) clearance with protease-resistant substitutions, without the albumin conjugation that produces the multi-day duration [2]. This is the single most important kinetic distinction for the compound: figures from one form cannot be transferred to the other. The [DAC vs no-DAC](/cjc-1295-dac) page details why. ## How much CJC-1295 should I take? There is no established human dose; CJC-1295 is not approved for human use. Published research used single subcutaneous 30-90 micrograms per kilogram doses in PK studies [1]. The fixed-dose "protocols" that circulate online are not derived from controlled human trials, so no figure here should be read as a use instruction. This site reports what studies administered, not what anyone should take. ## How much CJC-1295 DAC should I take? No validated human dose exists for the DAC form. Human PK studies used single 30, 60, or 90 micrograms per kilogram subcutaneous doses [1][3]. Because the DAC form has a 5.8-8.1 day half-life, it accumulates differently from short-acting no-DAC, which is one reason figures cannot be transferred between the two forms [1][2]. The research doses are reported as context, not as a regimen. ## How much CJC-1295 / ipamorelin should I take? No controlled human trial establishes a CJC-1295/ipamorelin dose. The pairing rests on a two-receptor (GHRH + GHRP) synergy rationale, but circulating fixed-dose protocols are not derived from clinical trials [5]. The mechanism supports combining the two pathways; it does not supply a validated dose for either compound in healthy adults, and this digest does not provide one. ## Where to inject CJC-1295? Published studies used subcutaneous injection, with intravenous administration appearing in the early GRF(1-29) PK work that motivated the long-acting program [1][2]. This reflects the route studied in the literature and is not a use recommendation for an unapproved compound. Oral administration is not viable: as a peptide, CJC-1295 has negligible oral bioavailability, which is why injection is the only route the research used [1]. ## What route was used in studies? Subcutaneous injection, primarily. Published CJC-1295 studies used the subcutaneous route; intravenous administration appears in the early native GRF(1-29) pharmacokinetic work [1][2]. The subcutaneous route is the one relevant to the DAC and no-DAC forms, and it is reported here as research context — what the studies did — rather than as guidance for handling an unapproved compound. ## How to reconstitute CJC-1295? It ships lyophilized and is reconstituted with bacteriostatic water and refrigerated in research handling [1]. Oral bioavailability is negligible, so subcutaneous injection is the route studied. The four substitutions confer DPP-IV and protease resistance, and the DAC conjugation confers the multi-day duration [2]. This describes laboratory handling of a research chemical, not human-use instructions. ## How is CJC-1295 handled in research settings? As a lyophilized peptide. The four substitutions (D-Ala2, Gln8, Ala15, Leu27) confer DPP-IV and protease resistance; the DAC conjugation confers the multi-day duration [2]. Stored cold and reconstituted with bacteriostatic water in research handling, it is administered subcutaneously because, like other peptides, it has negligible oral bioavailability [1]. None of this is a use protocol — it is how the literature describes preparing the material for study. ## Why no human dose can be quoted The published human data are limited to early-phase PK studies in healthy volunteers (Teichman 2006; Ionescu 2006) that measured hormone kinetics, not clinical outcomes [1][3]. A ConjuChem Phase 2 trial in HIV-associated visceral obesity (NCT00267527) was discontinued, and the DAC program did not advance. There are no large efficacy or long-term safety trials in healthy adults [1]. Without an outcome trial, there is no dose to recommend — only the doses that specific studies happened to administer, which this page reports as research context and nothing more. --- A curated night-board of the CJC-1295 record — each study, kinetic figure, and honest gap lit in its own tile and weighed by what the literature can actually carry, with no clinic behind the board and nothing here dispensed or sold.